Advances in nasopharyngeal carcinoma

Current Opinion in Oncology

Volumn 20, Issue 3, 2008, Pages 264-269

  Guigay, Joël ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Nasopharyngeal carcinoma; Positron emission tomography; Radiotherapy

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; PACLITAXEL; SORAFENIB; TAXANE DERIVATIVE;

BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ENDEMIC DISEASE; EPSTEIN BARR VIRUS; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; IMMUNOTHERAPY; METASTASIS; NASOPHARYNX CARCINOMA; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DNA, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; NASOPHARYNGEAL NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, INTENSITY-MODULATED; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 41949098205     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282fad846     Document Type: Review

References (56)

1. Chua DTT, Sham JST, Kwong DLW, et al. Treatment outcome after radiotherapy alone for patients with stage I-II nasopharyngeal carcinoma. Cancer 2003; 98:74-80.
2. O'Meara WP, Lee N. Advances in nasopharyngeal carcinoma. Curr Opin Oncol 2005; 17:225-230. A comprehensive review of recent advances in radiotherapy with an emphasis on IMRT.
3. Guigay J, Temam S, Bourhis J, et al. Nasopharyngeal carcinoma and therapeutic management: the place of chemotherapy. Ann Oncol 2006; 17 (Suppl 10):x304-x307.
4. Sanguineti G, Bossi P, Pou A, et al. Timing of chemotherapy and patient selection for locally advanced nasopharyngeal carcinoma. Clin Oncol 2003; 15:451-460.
5. Leung TW, Tung SY, Sze WK, et al. Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns. Head Neck 2005; 27:555-565. This retrospective study analyzed the outcome of more than one thousand NPC patients treated essentially with radiotherapy alone and showed a high incidence of metastasis in locally advanced patients.
6. Yu KH, Leung SF, Tung SY, et al. Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Head Neck 2005; 27:397-405.
7. Muylle K, Castaigne C, Flamen P. 18F-fluoro-2-deoxy-D-glucose positron emission tomographic imaging: recent developments in head and neck cancer. Curr Opin Oncol 2005; 17:249-253.
8. Liu FY, Lin CY, Chang JT, et al. 18F-FDG PET can replace conventional workup in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med 2007; 48:1614-1619. This prospective study compared the diagnosis efficacy of conventional staging and FDG-PET on 300 NPC patients focusing on primary M staging. Results demonstrated that FDG-PET can replace conventional imaging in this setting.
9. Chang JT, Chan SC, Yen TC, et al. Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 2005; 62:501-507.
10. Liu T, Xu W, Yan WL, et al. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best?: a systematic review. Radiother Oncol 2007; 85:327-335.
11. Hu WH, Zhang GY, Liu LZ, et al. Comparison between PET-CT and MRI in diagnosing nodal metastasis of nasopharyngeal carcinoma. Ai Zheng 2005; 24:855-860.
12. Zheng XK, Chen LH, Wang QS, Wu FB. Influence of [18F] fluorodeoxyglucose positron emission tomography on salvage treatment decision making for locally persistent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006; 65:1020-1025.
13. Chen YK, Su CT, Ding HJ, et al. Clinical usefulness of fused PET/CT compared with PET alone or CT alone in nasopharyngeal carcinoma patients. Anticancer Res 2006; 26:1471-1477.
14. Gordin A, Golz A, Daitzchman M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in patients with carcinoma of the nasopharynx: diagnostic accuracy and impact on clinical management. Int J Radiat Oncol Biol Phys 2007; 68:370-376.
15. Keryer-Bibens C, Pioche-Durieu C, Villemant C, et al. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 2006; 6:283.
16. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350:2461-2470.
17. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24:5414-5418. This large study showed that pretherapy circulating EBV-DBA load is an independent prognostic factor for survival.
18. Chan SL, Hui EP, Leung SF, et al. Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma. BMC Cancer 2006; 6:259.
19. Kalpoe JS, Dekker PB, van Krieken JH, et al. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area. J Clin Pathol 2006; 59:537-541.
20. Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma. Am J Clin Oncol 2002; 25:219-223.
21. Langendijk JA, Leemans R, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A metaanalysis of the published literature. J Clin Oncol 2004; 22:4604-4612.
22. Ma BBY, Chan ATC. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 2005; 103:22-31. A comprehensive review concerning the role of chemotherapy in the treatment of NPC patients.
23. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiation Oncology Biol Phys 2006; 64:47-56. This outstanding meta-analysis confirmed concurrent cisplatin-based chemoradiotherapy as a standard treatment for locally advanced NPC patients.
24. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer Stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005; 23:6730-6738.
25. Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005; 23:6966-6975.
26. Kong L, Lu JJ, Hu C, et al. The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy. Cancer 2006; 107:1287-1293.
27. Bourhis J, Guigay J, Temam S, Pignon JP. Chemo-radiotherapy in head and neck cancer. Ann Oncol 2006; 17 (Suppl 10):x39-x41.
28. Fang FM, Tsai WL, Chen HC, et al. Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: comparisons of four radiotherapy techniques. Cancer 2007; 109:313-321. This study showed that IMRT improved quality of life for NPC patients. The authors compared quality-of-life outcomes of 237 NPC survivors.
29. Wong ASC, Soo RA, Lu JJ, et al. Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma. Ann Oncol 2006; 17:1152-1157.
30. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578. This is an outstanding randomized study of radiotherapy plus cetuximab, which confirmed a benefit in outcome for the addition of cetuximab to radiation.
31. Rossi A, Molinari R, Boracchi P, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in loco-regional nasopharyngeal cancer: Results of 4-year multicenter randomized study. J Clin Oncol 1988; 6:1401-1410.
32. Chan ATC, Teo PML, Leung TW, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995; 33:569-577.
33. Al-Sarraf M, LeBlanc M, Shanker PG, et al. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998; 16:1310-1317.
34. Chi KH, Chang Y, Guo W, et al. A phase III study of adjuvant chemotherapy in advanced stage nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002; 52:1238-1244.
35. Cvitkovic E, Eschwege F, Rahal M, et al. Preliminary results of trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in Stage IV (≥N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression free survival. Int J Radiat Oncol Biol Phys 1996; 35:463-469.
36. Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer 1998; 83:2270-2283.
37. Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001; 19:1350-1357.
38. Haeryama M, Sakata K, Shirato H, et al. A prospective randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in advanced nasopharyngeal carcinoma. Cancer 2002; 94:2217-2223.
39. Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2005; 23:1118-1124. An update of two phase III studies showing that induction chemotherapy improved disease-specific survival in NPC patients. However, there was no improvement in overall survival.
40. Rischin D, Corry J, Smith J, et al. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 2002; 20:1845-1852.
41. Oh JL, Vokes EE, Kies MS, et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol 2003; 14:564-569.
42. Chan AT, Ma B, Lo D, et al. A phase II study of neoadjuvant taxol and carboplatin followed by concurrent cisplatin-radiotherapy in locoregionally advanced nasopharyngeal carcinoma with EBV DNA monitoring. J Clin Oncol 2004; 22:1-8.
43. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357:1695-1704.
44. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705-1715. These outstanding two phase III studies demonstrated a benefit in survival in HNSCC patients treated with TPF induction chemotherapy followed by chemoradiotherapy.
45. Hui EP, Ma BB, Leung SF, et al. Efficacy of neoadjuvant docetaxel and cisplatin followed by concurrent cisplatin-radiotherapy in locally advanced nasopharyngeal carcinoma (NPC): a randomized phase II study. J Clin Oncol 2007; 25(Suppl 18 ):308S [abstract 6037].
46. Leong SS, Wee J, Tay MH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a phase II trial using a triplet combination. Cancer 2005; 103:569-575.
47. Li YH, Wang FH, Jiang WQ, et al. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol 2008 [Epub ahead of print]. This recent phase II study is the first report of capecitabine and cisplatin combination as first line in metastatic NPC patients.
48. Fandi A, Bachouchi M, Azli N, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 2000; 18:1324-1330.
49. Airoldi M, Pedani F, Marchionatti S, et al. Carboplatin plus taxol is an effective third line regimen in recurrent undifferentiated nasopharyngeal carcinoma. Tumori 2002; 88:273-276.
50. Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinumbased chemotherapy. Oral Oncol 2003; 39:361-366.
51. Cruz JJ, Ocaña A, Del Barco E, Pandiella A. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 2007; 18:421-430. This comprehensive review focus on the biological bases and the clinical results of new targeted treatments in head and neck cancer.
52. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005; 23:3568-3576
53. [comment in J Clin Oncol 2005; 23:7757-7758; author reply 7758-7759]. This phase II study is the only published study, with the new combination, that enrolled heavily pretreated patients. Comments are also instructive.
54. Elser C, Siu LL, Winquist EW, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25:3766-3773.
55. Zheng H, Li LL, Hu DS, et al. Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol 2007; 4:185-196.
56. Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005; 105:1898-1904. An interesting study showing promising results of immunotherapy in NPC.